301333 R&G PharmaStudies
- 39.68
- -0.13-0.33%
R&G PharmaStudies News
R&G PharmaStudies: Announcement on the completion of the election of the board of directors and the board of supervisors and the appointment of senior management
R&G PharmaStudies: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
R&G PharmaStudies: Legal Opinion of Beijing Junhe Law Firm on the 2023 Annual General Meeting of Shareholders of Norske (Beijing) Pharmaceutical Technology Co., Ltd.
R&G PharmaStudies: Announcement of Resolutions of the First Meeting of the Fourth Board of Supervisors
R&G PharmaStudies: Announcement of Resolutions of the First Meeting of the Fifth Board of Directors
R&G PharmaStudies: Announcement on the election of employee representative supervisors of the fourth board of supervisors
R&G PharmaStudies: Announcement on the use of some overraised funds to permanently replenish working capital
R&G PharmaStudies: Announcement of Resolutions of the 16th Meeting of the Third Board of Supervisors
R&G PharmaStudies: Announcement on changing the special account for fund-raising
R&G PharmaStudies: Announcement on Additional Provisional Proposals for the 2023 Annual General Meeting of Shareholders and Supplementary Notice to the Shareholders' Meeting
R&G PharmaStudies: Announcement of Resolutions of the 20th Meeting of the Fourth Board of Directors
R&G PharmaStudies: China International Finance Corporation's verification opinion on the use of part of the overfunded capital by Norske (Beijing) Pharmaceutical Technology Co., Ltd. to permanently supplement working capital
R&G PharmaStudies: Announcement on the progress of joint investment and establishment of industrial funds and related transactions with professional institutions
R&G PharmaStudies: China International Finance Corporation's 2023 Follow-up Report on Norske (Beijing) Pharmaceutical Technology Co., Ltd.
Norsk: 301333 Norsk research activity information 20240423
Norsk: Rules of work for the Board of Directors Audit Committee
Norske: Annual Report 2023
Norsk: Announcement on the use of some idle funds raised and own funds for cash management
Norske: 2023 Independent Director Debriefing Report (Lan Lipeng)
Norsk: external guarantee system
Analysis
Price Target
No Data
